Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05664516 · ClinicalTrials.gov registry record · Phase 2

A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder

A Phase 2 study of Binge-Eating Disorder, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT05664516 is a Phase 2 study of Binge-Eating Disorder that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 1,142-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05664516, a Phase 2 study of Binge-Eating Disorder, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the impact of intranasal oxytocin vs placebo in patients with binge eating disorder or episodes of binging. We hypothesize that 8 weeks of intranasal oxytocin vs placebo will improve clinical outcomes \[reduction in bingeing frequency\], and have a satisfactory safety and tolerability profile. We will also explore the predictive value of changes in homeostatic appetite, reward sensitivity, and impulse control, the identified underlying mediators, as assessed 4 weeks into the intervention, for treatment success after 8 weeks of the intervention.

Conditions Studied

Binge-Eating Disorder

Interventions

  • DRUG Placebo
  • DRUG TNX-1900 (Tonix Pharmaceuticals)

Study Locations (1)

Massachusetts

  • Neuroendocrine Unit Research Center - Boston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-03-07
Est. Completion 2026-12
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05664516

The ClinicalTrials.gov registry entry for NCT05664516 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,142-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (95% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Binge-Eating Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05664516 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05664516 about?

NCT05664516 is a clinical study titled "A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder". This study evaluates the impact of intranasal oxytocin vs placebo in patients with binge eating disorder or episodes of binging. We hypothesize that 8 weeks of intranasal oxytocin vs placebo will improve clinical outcomes \[reduction in bingeing frequency\], and have a satisfactory safety and tolera...

What is the current status of trial NCT05664516?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-03-07. Estimated completion is 2026-12.

What conditions does trial NCT05664516 study?

This clinical trial studies the following conditions: Binge-Eating Disorder.

What interventions are being tested in trial NCT05664516?

The interventions under investigation include: Placebo (DRUG), TNX-1900 (Tonix Pharmaceuticals) (DRUG).

Who is sponsoring clinical trial NCT05664516?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05664516 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Binge-Eating Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Binge-Eating Disorder

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.